- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: 10 States Recalcitrant on Medicaid; FDA Aware of Formula Issue Before Recall; Senator Wants AmeriSourceBergen Probe
Ten states remain that have not expanded Medicaid and they are unlikely to do so; FDA was aware of contaminated infant formula months before the most recent recall; Sen. Tammy Duckworth asks the Federal Trade Commission to investigate AmeriSourceBergen over its distribution practices around the brand-name of mifepristone (Mifeprex).
Remaining 10 States Unlikely to Expand Medicaid
With North Carolina accompanying other states expanding Medicaid, 10 states remain holdouts and are unlikely to bend, reported The Washington Post. Supporters of extending Medicaid coverage to additional low-income adults have been met with Republican resistance in other states. Since 2017, advocates have put Medicaid expansion power in the hands of voters in 7 conservative states, saying it would help bring in tax dollars and assist rural hospitals, but this strategy might be almost dead, and possibly met with additional hurdles.
FDA Aware of Contaminated Formula Months Before Latest Recall
Last month, formula manufacturer Reckitt recalled145,000 cans of infant formula due to the “possibility of cross-contamination with Cronobacter sakazakii,” the deadly bacteria that jumpstarted the infant formula crisis in 2022, although FDA inspectors knew about the positive test linked to this recall in November, said Politico. Amid this news, the FDA, which has been criticized for moving too slowly to ensure formula safety, Tuesday released guidelines it said will strengthen the US formula market.
Duckworth Asks FTC to Investigate Abortion Pill Distributor
Sen. Tammy Duckworth (D-Ill.) is asking the Federal Trade Commission (FTC) to inspect reports that drug distributor AmeriSourceBergen is denying the brand-name distribution of mifepristone (Mifeprex) to retail pharmacies in certain states, but continues to sell directly to health providers, reported The Hill. In a letter sent Monday to the FTC chair, Duckworth accused the company of exploiting the political climate surrounding abortion medication to maximize profits. Mifepristone is 1 of 2 drugs approved by the FDA for medication abortion. AmeriSourceBergen is the only distributor of the brand name, which can significantly impact access. Pharmacies can still dispense the generic version if they can access it.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
